Biosimilars: from technical to pharmacoeconomic considerations. 30th Rencontres Nationales de Pharmacologie et Recherche clinique pour l'Innovation et l'Evaluation des Technologies de Santé. Tables rondes

Thérapie

Volumn 70, Issue 1, 2015, Pages 37-55

  Girault, Danièle ^a   Trouvin, Jean Hugues ^b   Blachier Poisson, Corinne ^c   Gary, François ^d   Laloye, Didier ^e   Bergmann, Jean François ^f   Casadevall, Nicole ^g   Delval, Cécile ^h   De Sahb Berkovitch, Rima ⁱ   Fagon, Jean Yves ^j   Gersberg, Marta ^k   Lassale, Catherine ^l   Lechat, Philippe ^m   Le Jeunne, Claire ⁿ   Montastruc, Jean Louis ^o   Prugnaud, Jean Louis ^g   Ratignier Carbonneil, Christelle ^p   Rey Coquais, Cécile ^q  

^a NOVARTIS PHARMA K K   (Japan)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Laboratoire Amgen   (France)

^d Laboratoires Sandoz   (France)

^e Laboratoire HOSPIRA France   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h ANSM   (France)

ⁱ MSD France   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k MGersberg Conseil   (France)

^l LEEM   (France)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ Institut Cochin

^o TOULOUSE UNIVERSITY HOSPITAL   (France)

^p Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

^q PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT;

DRUG COST; ECONOMICS; FINANCIAL MANAGEMENT; FRANCE; HUMAN; LEGISLATION AND JURISPRUDENCE; MEDICAL RECORD; ORGANIZATION AND MANAGEMENT; PHARMACY; POSTMARKETING SURVEILLANCE; PUBLIC HEALTH; REIMBURSEMENT; RISK MANAGEMENT; STANDARDS; SUPPLY AND DISTRIBUTION;

BIOSIMILAR PHARMACEUTICALS; DRUG COSTS; FRANCE; HUMANS; MARKETING OF HEALTH SERVICES; MEDICAL RECORDS; NATIONAL HEALTH PROGRAMS; PHARMACIES; PRODUCT SURVEILLANCE, POSTMARKETING; REIMBURSEMENT MECHANISMS; RISK MANAGEMENT;

EID: 84924709591     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2015003     Document Type: Article

References (0)